Table 3.
Comparison of different multicentre HFpEF pharmacological trials with functional capacity endpoints
| Name of trial | N | Investigational drug | Comparator | Duration of follow‐up | 6 min walking distance (m) | Peak VO2 (mL/min/kg) |
|---|---|---|---|---|---|---|
| Aldo‐DHF 19 | 422 | Spironolactone 25 mg/d | Placebo | 12 months | −15 (P = 0.02) | −0.1 (P = 0.81) |
| NEAT‐HFpEF 20 | 110 | Isosorbidmono‐nitrate 120 mg/d | Placebo | 6 weeks | +0.1 (P = 0.91) | NA |
| Anemia in HFpEF 21 | 56/10 | Epoetin alpha | Placebo | 6 months | +11 (P = 0.52) | +2.2 (P < 0.03) |
| RELAX 22 | 216 | Sildenafil 60 mg/d | Placebo | 12 weeks | −10 (P = 0.92) | +0.01 (P = 0.98) |
| EDIFY 23 | 179 | Ivabradine 15 mg/d | Placebo | 8 months | −3.8 (P = 0.88) | NA |
| INDIE‐HFpEF 24 | 105 | Nitrate 138 mg/d | Placebo | 6 weeks | NA | −0.20 (P = 0.27) |
| PANACHE 25 | 305 | Neladenoson 5–30 mg/d | Placebo | 20 weeks | 14–29 (P = n.s.) | NA |
d, day; NA, not available; n.s., non‐significant